[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346532-105":59,"doc-detail-346532-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-n-glycoproteomic-atlas-of-patient-derived-xenografts-uncovers-fat2-as-an-actionable-surface-target","Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target","","Govindarajan and colleagues use N-glycoproteomics and patient-derived xenograft (PDX) models to map the in vivo cancer cell surfaceome and build Glyco PDXplorer, a pan-cancer platform for target discovery. The study prioritizes proteins with favorable expression profiles for immunotherapeutic targeting and identifies FAT2 as a previously undescribed actionable antigen. FAT2 shows minimal normal tissue expression, is enriched in squamous cancers, and supports tumor growth, adhesion, and integrin-PI3K signaling, with FAT2 CAR-T cells producing anti-tumor activity in preclinical models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-n-glycoproteomic-atlas-of-patient-derived-xenografts-uncovers-fat2-as-an-actionable-surface-target/346532/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-n-glycoproteomic-atlas-of-patient-derived-xenografts-uncovers-fat2-as-an-actionable-surface-target/346532.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is Glyco PDXplorer and what problem does it address?","Question",{"text":112,"@type":113},"Glyco PDXplorer is an in vivo pan-cancer atlas of cancer-derived surface proteins. It is built to decode the cancer cell surfaceome despite technical challenges in profiling surface proteins.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was FAT2 identified in this study?",{"text":117,"@type":113},"The authors use an N-glycoproteomics analysis of 85 patient-derived xenografts and develop a target discovery pipeline. FAT2 is validated as a squamous-cancer-enriched surface protein with minimal normal tissue detection.",{"name":119,"@type":110,"acceptedAnswer":120},"What functional role does FAT2 play, and what did CAR-T cells show?",{"text":121,"@type":113},"FAT2 is described as essential for head and neck squamous cancer growth and adhesion, mediated through surface architecture and integrin-PI3K signaling. FAT2-targeting CAR-T cells demonstrate anti-tumor activity in preclinical models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346532,1790524093,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Article  \nPan-cancer N-glycoproteomic atlas of patientderived xenografts uncovers FAT2 as an actionable surface target  \nGraphical abstract Authors  \nPan-cancer platform for cell surface target  \npatient-derived xenografts  \nCancer selective expression  \nEssential for tumor growth  \nTherapeutic potential  \nDiscovery and validation of FAT2 as a novel actionable surface protein  \nMeinusha Govindarajan, Salvador Mejia-Guerrero,  \nShawn C. Chafe,   , Ismael Samudio, Sheila K. Singh, Thomas Kislinger  \nCorrespondence  \n[thomas.kislinger@utoronto.ca](thomas.kislinger@utoronto.ca)  \nIn brief  \nGovindarajan et al. leverage Nglycoproteomics and PDX models to decode the in vivo cancer cell surfaceome and establish Glyco PDXplorer—a target discovery platform. The identification and validation of FAT2 as a previously undescribed, actionable antigen demonstrates the utility of Glyco PDXplorer for uncovering therapeutic vulnerabilities.  \nHighlights  \n• Pan-cancer landscape of cancer-derived cell surface proteins detected in vivo  \n• Discovery pipeline to prioritize proteins as immunotherapy target candidates  \n• Validation of FAT2 as an SCC surface protein with minimal normal tissue expression  \n• FAT2 CAR-T cells demonstrate anti-tumor activity in preclinical models  \nGovindarajan et al., 2026, Cell Reports Medicine 7, 102578  \nFebruary 17, 2026 © 2025 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2025.102578](https://doi.org/10.1016/j.xcrm.2025.102578)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nPan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target  \nMeinusha Govindarajan,1,2,11 Salvador Mejia-Guerrero,2,11 Shawn C. Chafe,3,4 Shahbaz Khan,2 Wei Shi,2 Matthew Waas,2 Martin A. Rossotti,5 Amanda Khoo,1,2 Lydia Y. Liu,1,2 Vladimir Ignatchenko,2 Simona Principe,2 Lusia Sepiashvili,1,2 Greg Hussack,5 Nazanin Tatari,3,6 Chitra Venugopal,3,4 Petar Miletic,3,4 Maxwell Topley,3,6 Shan Grewal,3,4  \nDillon McKenna,3,6 Lucas C. Asselstine,3,4 Maria-Jose Sandi,2 Nhu-An Pham,2 Alison Casey,2 Hyeyeon Kim,1,2 Christina Karamboulas,2 Jalna Meens,2 Peter Bergqvist,7 Begonia Silva,7 Patrick Chan,7 Liza Cerna-Portillo,7 Jasmine Chin,7 Abilasha Rao-Bhatia,7 Ming-Sound Tsao,1,2 Rama Khokha,1,2 Susie Su,8 Wei Xu,2,8 David Goldstein,2,9 Laurie Ailles,1,2 Vuk Stambolic,1,2 Fei-Fei Liu,1,2,10 Emma Cummins,7 Ismael Samudio,7 Sheila K. Singh,3,4,6 and Thomas Kislinger1,2,12,*  \n1Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada  \n2Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada  \n3Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON L8S 4M1, Canada  \n4Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 1C7, Canada  \n5Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, Ottawa, ON K1A 0R6, Canada  \n6Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada  \n7adMare BioInnovations, Vancouver, BC V6T 1Z3, Canada  \n8Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada  \n9Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, ON M5S 3H2, Canada  \n10Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada  \n11These authors contributed equally  \n12Lead contact  \n*Correspondence: [thomas.kislinger@utoronto.ca](thomas.kislinger@utoronto.ca)[ ](thomas.kislinger@utoronto.ca)[https://doi.org/10.1016/j.xcrm.2025.102578](https://doi.org/10.1016/j.xcrm.2025.102578)  \nSUMMARY  \nCell surface proteins offer significant cancer therapeutic potential attributable to their accessible membrane localization and central roles in cellular signaling, yet their promise remains largely untapped due to technical challenges inherent to profiling them. Here, we employ N-glycoproteomics to analyze 85 patient-de","cbCaijohIKU1GGzG","https://ap.wps.com/l/cbCaijohIKU1GGzG","pdf",16153793,33,"English","# Summary\n# Highlights\n# Article Overview\n## Methods and platform (Glyco PDXplorer)\n## Target discovery and FAT2 validation\n## Functional impact and CAR-T preclinical results","[{\"question\":\"What is Glyco PDXplorer and what problem does it address?\",\"answer\":\"Glyco PDXplorer is an in vivo pan-cancer atlas of cancer-derived surface proteins. It is built to decode the cancer cell surfaceome despite technical challenges in profiling surface proteins.\"},{\"question\":\"How was FAT2 identified in this study?\",\"answer\":\"The authors use an N-glycoproteomics analysis of 85 patient-derived xenografts and develop a target discovery pipeline. FAT2 is validated as a squamous-cancer-enriched surface protein with minimal normal tissue detection.\"},{\"question\":\"What functional role does FAT2 play, and what did CAR-T cells show?\",\"answer\":\"FAT2 is described as essential for head and neck squamous cancer growth and adhesion, mediated through surface architecture and integrin-PI3K signaling. FAT2-targeting CAR-T cells demonstrate anti-tumor activity in preclinical models.\"}]","Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target | PDF",1790061859,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe4ba4d9f66818b0d6f0e22f3334327b.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1ab0c783771bb84a153d6744a5a2b30.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a44cfb06edeeca0227e856647bf0dedb.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf52c0d0436182fe8a8b567c80f68abc.webp",980,1272]